<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01825941</url>
  </required_header>
  <id_info>
    <org_study_id>13-02-071</org_study_id>
    <nct_id>NCT01825941</nct_id>
  </id_info>
  <brief_title>Diphenhydramine for Acute Migraine</brief_title>
  <official_title>Diphenhydramine as Adjuvant Therapy for Acute Migraine. A Randomized Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parenteral diphenhydramine is commonly used as adjuvant therapy for acute migraine despite
      the fact that data supporting this practice do not exist. The investigators propose a
      randomized double blind study to test the hypothesis that 50mg of intravenous
      diphenhydramine, when added to standard migraine therapy, will result in a greater rate of
      sustained headache relief than standard migraine therapy alone. For this study, standard
      migraine therapy will be 10mg of intravenous metoclopramide. Sustained headache relief is
      defined as achieving a headache level of &quot;mild&quot; or &quot;none&quot; within two hours and maintaining a
      level of &quot;mild&quot; or &quot;none&quot; for 48 hours. Patients who present to the Montefiore emergency room
      (Bronx, NY) with an acute migraine will be approached for participation. They will be
      screened for medication contra-indications and non-migraine etiologies of headache. The study
      will be randomized. Assignment will be concealed. Participants and researchers will be
      blinded. Efficacy outcomes and adverse events will be assessed every half hour for two hours
      in the Emergency Department and by telephone 48 hours after medication administration. A
      sample size calculation, based on pilot data, revealed the need for 374 participants. An
      interim analysis will be performed after 200 participants have been enrolled with the goal of
      assessing for lack of conditional power.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Sustained Headache Relief Assessed by Self-evaluation</measure>
    <time_frame>up to 2 hours in Emergency Department, 48 hours after discharge from Emergency Department</time_frame>
    <description>Sustained headache relief is defined as achieving a headache level of &quot;mild&quot; or &quot;none&quot; within two hours and maintaining a level of &quot;mild&quot; or &quot;none&quot; for 48 hours. Patient self-evaluated pain level is solicited every half hour for two hours in the Emergency Department and then by telephone 48 hours after discharge from emergency department</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Metoclopramide + Diphenhydramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopramide + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Metoclopramide 10mg + placebo, administered intravenously over 15 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoclopramide</intervention_name>
    <description>10 milligrams, administered intravenously over 15 minutes</description>
    <arm_group_label>Metoclopramide + Diphenhydramine</arm_group_label>
    <arm_group_label>Metoclopramide + placebo</arm_group_label>
    <other_name>Reglan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diphenhydramine</intervention_name>
    <description>50 milligrams, administered intravenously over 15 minutes</description>
    <arm_group_label>Metoclopramide + Diphenhydramine</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Metoclopramide + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute migraine headache

          -  Present to our emergency room in the Bronx, NY for treatment of migraine headache

        Exclusion Criteria:

          -  Temperature &gt; 100.3 F

          -  Pheochromocytoma

          -  Seizure disorder

          -  Parkinson's disease

          -  Use of monoamine oxidase (MAO) inhibitors

          -  Use of anti-rejection transplant medications

          -  Use of potassium supplements

          -  Use of pramlintide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin W Friedman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 2, 2013</study_first_submitted>
  <study_first_submitted_qc>April 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2013</study_first_posted>
  <results_first_submitted>May 7, 2018</results_first_submitted>
  <results_first_submitted_qc>May 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 8, 2018</results_first_posted>
  <last_update_submitted>July 2, 2018</last_update_submitted>
  <last_update_submitted_qc>July 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin W. Friedman, MD</investigator_full_name>
    <investigator_title>Associate professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>headache</keyword>
  <keyword>metoclopramide</keyword>
  <keyword>diphenhydramine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Protocol anticipated enrollment of around 400 participants, however Data Safety Monitoring Board recommended enrollment cut to approximately half</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Metoclopramide + Diphenhydramine</title>
          <description>Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes
metoclopramide: 10 milligrams, administered intravenously over 15 minutes
diphenhydramine: 50 milligrams, administered intravenously over 15 minutes</description>
        </group>
        <group group_id="P2">
          <title>Metoclopramide + Placebo</title>
          <description>Metoclopramide 10mg + placebo, administered intravenously over 15 minutes
metoclopramide: 10 milligrams, administered intravenously over 15 minutes
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metoclopramide + Diphenhydramine</title>
          <description>Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes
metoclopramide: 10 milligrams, administered intravenously over 15 minutes
diphenhydramine: 50 milligrams, administered intravenously over 15 minutes</description>
        </group>
        <group group_id="B2">
          <title>Metoclopramide + Placebo</title>
          <description>Metoclopramide 10mg + placebo, administered intravenously over 15 minutes
metoclopramide: 10 milligrams, administered intravenously over 15 minutes
placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="208"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="104"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="11"/>
                    <measurement group_id="B2" value="36" spread="10"/>
                    <measurement group_id="B3" value="35" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="104"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="104"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of headache Prior to Study</title>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="104"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="24" upper_limit="96"/>
                    <measurement group_id="B2" value="48" lower_limit="16" upper_limit="72"/>
                    <measurement group_id="B3" value="48" lower_limit="24" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Sustained Headache Relief Assessed by Self-evaluation</title>
        <description>Sustained headache relief is defined as achieving a headache level of &quot;mild&quot; or &quot;none&quot; within two hours and maintaining a level of &quot;mild&quot; or &quot;none&quot; for 48 hours. Patient self-evaluated pain level is solicited every half hour for two hours in the Emergency Department and then by telephone 48 hours after discharge from emergency department</description>
        <time_frame>up to 2 hours in Emergency Department, 48 hours after discharge from Emergency Department</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide + Diphenhydramine</title>
            <description>Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes
metoclopramide: 10 milligrams, administered intravenously over 15 minutes
diphenhydramine: 50 milligrams, administered intravenously over 15 minutes</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide + Placebo</title>
            <description>Metoclopramide 10mg + placebo, administered intravenously over 15 minutes
metoclopramide: 10 milligrams, administered intravenously over 15 minutes
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Headache Relief Assessed by Self-evaluation</title>
          <description>Sustained headache relief is defined as achieving a headache level of &quot;mild&quot; or &quot;none&quot; within two hours and maintaining a level of &quot;mild&quot; or &quot;none&quot; for 48 hours. Patient self-evaluated pain level is solicited every half hour for two hours in the Emergency Department and then by telephone 48 hours after discharge from emergency department</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metoclopramide + Diphenhydramine</title>
          <description>Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes
metoclopramide: 10 milligrams, administered intravenously over 15 minutes
diphenhydramine: 50 milligrams, administered intravenously over 15 minutes</description>
        </group>
        <group group_id="E2">
          <title>Metoclopramide + Placebo</title>
          <description>Metoclopramide 10mg + placebo, administered intravenously over 15 minutes
metoclopramide: 10 milligrams, administered intravenously over 15 minutes
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Drowsy</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="104"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin W. Friedman, MD, MS</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>718-920-6266</phone>
      <email>befriedm@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

